The GH/IGF-1 system in critical illness

Elijah, Itoro; Branski, Ludwik K.; Finnerty, Celeste C.; Herndon, David N.

doi:10.1016/j.beem.2011.06.002

Cited by 73 publications

(55 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, IGF-1 has the potential to become a biomarker and therapeutic target of sepsis. It has been demonstrated that IGF-1 levels in critical patients typically exhibit a declining trend (24). Therefore, this study focused on the changes in IGF-1 levels in patients with sepsis.…”

Section: Discussionmentioning

confidence: 99%

IGF-1 may predict the severity and outcome of patients with sepsis and be associated with microRNA-1 level changes

Zhang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. IGF-1 functions as an anti-oxidative stress molecule and some critical patients with sepsis have a lower level of serum IGF-1. However, the association between IGF-1 and the severity or prognosis of sepsis remains unclear. This study aimed to elucidate the relationship between serum IGF-1 levels and the severity and prognosis of sepsis, and the possible mechanism was analyzed. Clinical characteristics of patients with sepsis were recorded and analyzed. Serum IGF-1 levels and micro (mi)RNA-1 levels were tested using radioimmunoassay and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, respectively. The A549 cell line and HKC cell line were cultured in vitro and exposed to H 2 O 2 with or without IGF-1 treatment. Cell death was detected by analyzing cell death markers via ELISA kits, and miRNA-1 levels were detected after H 2 O 2 exposure using RT-qPCR analysis. miRNA-1 in cells was upregulated by transfection and IGF-1 mRNA was detected to determine its relationship with miRNA-1. Once again, cell ELISA kits were used to analyze cell death markers after transfection. Serum IGF-1 levels were reduced in patients with sepsis, whereas miRNA-1 levels were higher (P<0.05 vs. healthy control). Patients in the septic shock subgroup or dead patients had the lowest IGF-1 levels and the highest miRNA-1 levels (P<0.05 vs. sepsis and severe sepsis). IGF-1 levels were inversely proportional to the miRNA-1 level. In vitro, IGF-1 reduced the cell death caused by H 2 O 2 . miRNA-1 transfection effectively increased the sensitivity of cells to H 2 O 2 damage by reducing the expression of IGF-1, which was able to prevent cells from injury caused by H 2 O 2 . The transfection of negative control miRNA did not influence the level of IGF-1 miRNA and the sensitivity to H 2 O 2 damage. In conclusion, low IGF-1 levels in patients with sepsis may predict increased severity of the condition and poor prognosis. The possible mechanism is that the excessive miRNA-1 levels reduce IGF-1 levels, resulting in insufficient anti-oxidative action by IGF-1 which increases the injury caused by oxidative stress in patients with sepsis.

show abstract

Section: Discussionmentioning

confidence: 99%

IGF-1 may predict the severity and outcome of patients with sepsis and be associated with microRNA-1 level changes

Zhang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The use of recombinant human growth hormone (rhGH) has been studied extensively in various critically ill patients [45]. A RCT in which rhGH (0.15 IU/kg) was administered for three weeks during a two-month course of respiratory rehabilitation in COPD patients revealed an increase in the lean body mass in the rhGH-treated group (2.3 ± 1.6 kg) and in the control group (1.1 ± 0.9 kg) ( p < 0.05), with no changes observed in respect of the exercise tolerance (6-min walking distance, 6 MWD), respiratory muscle strength, or the grip strength [46].…”

Section: Adipokines and Hormones Affecting The Nutritional Statusmentioning

confidence: 99%

Undernutrition in Patients with COPD and Its Treatment

et al. 2013

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disorder of the lung and whole body caused mainly by tobacco smoking. Patients with advanced COPD are in a state of undernutrition, referred to as pulmonary cachexia; the exercise performance and quality of life (QOL) of these patients are deteriorated, the vital prognosis is unfavorable, and the medico-economic burden posed by poorly nourished COPD patients is high. The mainstays of COPD treatment are pharmacotherapy, mainly with bronchodilators, and non-pharmacotherapeutic approaches such as respiratory rehabilitation and nutrition counseling. Nutritional supplement therapy, consisting primarily of high calorie intake, has been demonstrated to be effective for maintaining and improving the muscle strength and exercise tolerance in poorly nourished COPD patients. The efficacy of intake of various nutrients, besides a high calorie intake, for amelioration of the disease state of COPD has also been reported. The roles of adipokines in the pathophysiology of COPD have begun to receive attention recently, and not only their regulatory effects on appetite and nutritional status, but also their influence on systemic inflammation have been increasingly clarified. We review the papers on COPD and nutrition and discuss the role of nutritional supplement therapy in the treatment of COPD.

show abstract

“…The Growth Hormone Research Society has recommended the cessation of rhGH (and by inference rIGF-I) use during critical illness [46][47][48][49] .…”

Section: Igf-i As a Therapeutic Agentmentioning

confidence: 99%